Online citations, reference lists, and bibliographies.

Quality By Design (QbD) And The Development And Manufacture Of Drug Substance

G. Steele
Published 2018 · Computer Science
Referenced 1 time by Citationsy Users

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1021/OP2003024
Modeling-Based Approach Towards Quality by Design for the Ibipinabant API Step
Shawn B Brueggemeier (2012)
10.1007/s12247-008-9033-3
PQLI Definition of Criticality
R. Nosal (2008)
10.1016/J.JPROCONT.2008.06.002
Modelling and control of combined cooling and antisolvent crystallization processes
Z. Nagy (2008)
10.1021/OP800249R
Crystallisation Design Space: Avoiding a Hydrate in a Water-Based Process
Simon Black (2009)
10.1021/OP100072Y
Selection and Development of the Manufacturing Route for EP1 Antagonist GSK269984B
Matthew Whiting (2010)
10.1016/S0022-0248(97)00119-X
ATR FTIR spectroscopy for in situ measurement of supersaturation
Dilum D. Dunuwila (1997)
10.1021/OP4000972
Understanding and Avoidance of Agglomeration During Drying Processes: A Case Study
Melissa B.L. Birch (2013)
10.1021/CG049837M
Toward a molecular understanding of crystal agglomeration
Michael Brunsteiner (2005)
10.1021/OP050107C
An In-Line Study of Oiling Out and Crystallization
Emilie Deneau (2005)
10.1021/OP300336N
On the Measurement of Solubility
Simon Black (2013)
10.1205/CHERD06229
In Situ Raman Spectroscopy for In-Line Control of Pharmaceutical Crystallization and Solids Elaboration Processes: A Review
G. Févotte (2007)
10.1016/J.JCRYSGRO.2006.05.072
Polymorphic transformation of L-glutamic acid monitored using combined on-line video microscopy and X-ray diffraction
Spoorthi Dharmayat (2006)
10.1021/OP500373E
Route Design in the 21st Century: The ICSYNTH Software Tool as an Idea Generator for Synthesis Prediction
A. Bøgevig (2015)
10.1021/CR050982W
Critical assessment of pharmaceutical processes--A rationale for changing the synthetic route.
M. Butters (2006)
10.1021/OP900242X
Application of Quality by Design Principles to Support Development of a Control Strategy for the Control of Genotoxic Impurities in the Manufacturing Process of a Drug Substance
Zadeo Cimarosti (2010)
10.1002/jps.22754
Interdependence of drug substance physical properties and corresponding quality control strategy.
Yong Cui (2012)
10.1007/s12247-013-9150-5
A Design Space Verification Protocol for a Small Molecule Drug Substance
Timothy J. N. Watson (2013)
10.1021/CG2003029
Quality by Design (QbD)-Based Crystallization Process Development for the Polymorphic Drug Tolbutamide
Satyanarayana Thirunahari (2011)
10.1163/1568552042456205
Industrial crystallization for fine chemicals
K. Carpenter (2004)
10.1021/OP400333U
Correlation of Drug Substance Particle Size Distribution with Other Bulk Properties to Predict Critical Quality Attributes
Henry G. Morrison (2015)
10.1016/S0255-2701(98)00083-X
Vacuum drying of a multicomponent pharmaceutical product having different pseudo-polymorphic forms
S. Laurent (1999)
10.1016/S0022-0248(01)02284-9
Some aspects of the importance of metastable zone width and nucleation in industrial crystallizers
J. Ulrich (2002)
10.1021/OP050091Q
Control of the Particle Properties of a Drug Substance by Crystallization Engineering and the Effect on Drug Product Formulation
Saehoon Kim (2005)
10.1021/OP100223A
In-Process Monitoring and Control of Supersaturation in Seeded Batch Cooling Crystallisation of l-Glutamic Acid: From Laboratory to Industrial Pilot Plant
Shahid Khan (2011)
10.1016/j.bmc.2010.06.029
Process R&D under the magnifying glass: organization, business model, challenges, and scientific context.
H -J. Federsel (2010)
10.1021/OP800067V
Identification of Critical Process Impurities and Their Impact on Process Research and Development
Yande Huang (2008)
10.1021/op960033s
Purification of Dirithromycin. Impurity Reduction and Polymorph Manipulation
D. D. Wirth (1997)
10.1016/j.ijpharm.2012.03.029
Enhancing crystalline properties of a cardiovascular active pharmaceutical ingredient using a process analytical technology based crystallization feedback control strategy.
Ali N. Saleemi (2012)
10.1021/OP500126U
Control Strategy for the Manufacture of Brivanib Alaninate, a Novel Pyrrolotriazine VEGFR/FGFR Inhibitor
Paul C. Lobben (2015)
10.1002/AIC.690470115
Experimental design and inferential modeling in pharmaceutical crystallization
Timokleia Togkalidou (2001)
10.1023/A:1011052932607
Ritonavir: An Extraordinary Example of Conformational Polymorphism
John Bauer (2004)
10.1021/OP100209C
Application of Quality by Design Principles for the Definition of a Robust Crystallization Process for Casopitant Mesylate
C. Castagnoli (2010)
10.1007/s12247-008-9028-0
The Use of Routine Process Capability for the Determination of Process Parameter Criticality in Small-molecule API Synthesis
Kevin D. Seibert (2008)
10.1007/s12247-008-9035-1
PQLI Control Strategy Model and Concepts
B. Davis (2008)
10.1252/jcej.24.237
Solubilities and Crystallization Behavior of Cimetidine Polymorphic Forms A and B
S. Sudo (1991)
10.1021/OP010013C
Crystallisation of the Stable Polymorph of Hydroxytriendione: Seeding Process and Effects of Purity
W. Beckmann (2001)
10.1021/OP500187U
Case Studies in the Applicability of Drug Substance Design Spaces Developed on the Laboratory Scale to Commercial Manufacturing
N. Thomson (2015)
10.1016/J.JPBA.2006.03.013
A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials.
P. F. Gavin (2006)
10.1039/C4GC01149J
A survey of solvent selection guides
D. Prat (2014)
10.1021/OP980029B
Development of a Seeding Technique for the Crystallization of the Metastable A Modification of Abecarnil
W. Beckmann (1998)
10.1016/S1385-8947(02)00067-0
Alternative multiphase reactors for fine chemicals: A world beyond stirred tanks?
E. Stitt (2002)
10.1002/AIC.11555
From Form to Function: Crystallization of Active Pharmaceutical Ingredients
N. Variankaval (2008)
10.1021/OP700293P
Industrial Applications of Online Monitoring of Drying Processes of Drug Substances Using NIR
Jens Burgbacher (2008)
10.1021/OP900281M
Application of ATR-UV Spectroscopy for Monitoring the Crystallisation of UV Absorbing and Nonabsorbing Molecules
Pascal Billot (2010)
10.1021/OP300126E
Application of the Quality by Design Principles for the Development of the Crystallization Process for a Piperazinyl-Quinoline and Definition of the Control Strategy for Form 1
Zadeo Cimarosti (2012)
10.1016/J.CES.2013.05.035
Investigation of factors affecting isolation of needle-shaped particles in a vacuum-agitated filter drier through non-invasive measurements by Raman spectrometry
P. Hamilton (2013)
10.1016/J.POWTEC.2010.08.026
Impact of downstream processing on crystal quality during the precipitation of a pharmaceutical product
N. Estime (2011)
10.1016/j.drudis.2010.11.008
Early chemical development at Legacy Wyeth Research.
M. K. O'brien (2011)
10.1002/CEAT.200500372
Seeding during Batch Cooling Crystallization – An Initial Approach to Heuristic Rules
Andrea Warstat (2006)
10.1021/OP9001438
A Practical Approach for Using Solubility to Design Cooling Crystallisations
Frans L. Muller (2009)
10.1007/s12247-011-9109-3
Model-Guided Design Space Development for a Drug Substance Manufacturing Process
Justin Lockheart Burt (2011)
10.1021/ACS.OPRD.5B00063
Effects of Comilling on Final API Physical Attributes
Anne E. Mohan (2015)
10.1002/JPS.10375
Determination and differentiation of surface and bound water in drug substances by near infrared spectroscopy.
G. Zhou (2003)
10.1021/OP034107T
Crystallization Process Development of an Active Pharmaceutical Ingredient and Particle Engineering via the Use of Ultrasonics and Temperature Cycling
S. Kim (2003)
10.1252/JCEJ.37.1224
The Effects of Impurities on Crystallization of Polymorphs of a Drug Substance AE1-923
M. Okamoto (2004)
Optimize batch crystallization
W. P. Moore (1994)
10.1021/op900154c
An Efficient Laboratory Automation Concept for Process Chemistry
Christian Bernlind (2009)
10.1039/c1cs15041c
The importance of green chemistry in process research and development.
P. J. Dunn (2012)
10.1021/ACS.OPRD.5B00008
Real-Time Monitoring and Control of Critical Process Impurities during the Manufacture of Fostamatinib Disodium
Richard Hart (2015)
10.1021/ACS.OPRD.5B00079
Part 3: Designation and Justification of API Starting Materials: Proposed Framework for Alignment from an Industry Perspective
Margaret M. Faul (2015)
10.1021/OP500003K
Large-Scale Crystallization of a Pure Metastable Polymorph by Reaction Coupling
Hung Lin Lee (2014)
10.1016/j.jpba.2010.11.039
Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
N. Saravana Raman (2011)
10.1021/OP900237X
Continuous Crystallization of Pharmaceuticals Using a Continuous Oscillatory Baffled Crystallizer
S. Lawton (2009)
10.1021/OP0600052
Constant Supersaturation Control of Antisolvent-Addition Batch Crystallization
N. Nonoyama (2006)
10.1016/j.ejps.2011.03.004
Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
A. Giordani (2011)
10.1007/s12247-008-9032-4
PQLI Key Topics - Criticality, Design Space, and Control Strategy
T. García (2008)
10.1039/C0GC00918K
Expanding GSK's solvent selection guide ― embedding sustainability into solvent selection starting at medicinal chemistry
R. K. Henderson (2011)
10.1016/J.ADDR.2003.10.012
Applications of process analytical technology to crystallization processes.
L. Yu (2004)
10.1021/CR040677V
Process chemistry: The science, business, logic, and logistics.
T. Y. Zhang (2006)
10.1021/OP0500077
Towards a PAT-Based Strategy for Crystallization Development
M. Birch (2005)
10.1007/s12247-008-9034-2
PQLI Design Space
J. Lepore (2008)
10.1021/OP900341A
Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and Perspective
Derek Robinson (2010)
10.1021/OP500169M
Design of Experiments (DoE) and Process Optimization. A Review of Recent Publications
S. Weissman (2015)
10.1039/B602413K
Analysis of the reactions used for the preparation of drug candidate molecules.
J. S. Carey (2006)
10.1021/OP900019B
Endoscopy-Based in Situ Bulk Video Imaging of Batch Crystallization Processes
Levente Simon (2009)
10.1021/ACS.OPRD.5B00149
Optimization of a Crystallization Process for Orantinib Active Pharmaceutical Ingredient by Design of Experiment To Control Residual Solvent Amount and Particle Size Distribution
Hiroyasu Sato (2015)
10.1021/OP300326B
How To Use the Lasentec FBRM Probe on Manufacturing Scale
Neil K. Adlington (2013)
10.1021/OP500059K
Part 1: A Review and Perspective of the Regulatory Guidance to Support Designation and Justification of API Starting Material
Margaret M. Faul (2014)
10.1021/OP2000095
Development of a Fully Telescoped Synthesis of the S1P1 Agonist GSK1842799
Michael S. Anson (2011)
10.1021/OP0000778
Seeding the Desired Polymorph: Background, Possibilities, Limitations, and Case Studies
W. Beckmann (2000)
10.1021/OP500056A
An Integrated Process Analytical Technology (PAT) Approach for Pharmaceutical Crystallization Process Understanding to Ensure Product Quality and Safety: FDA Scientist’s Perspective
Huiquan Wu (2015)
10.1021/OP4002565
Sanofi’s Solvent Selection Guide: A Step Toward More Sustainable Processes
D. Prat (2013)
10.1021/ACS.OPRD.5B00088
Industry Perspectives on Process Analytical Technology: Tools and Applications in API Manufacturing
Shailendra V. Bordawekar (2015)
10.1021/OP050081P
In-Line Analysis of Impurity Effects on Crystallisation
Claire I. Scott (2005)
10.1007/s10668-012-9365-5
A system view of solvent selection in the pharmaceutical industry: towards a sustainable choice
S. Pérez-Vega (2012)
10.1021/OP400358B
Industry Perspectives on Process Analytical Technology: Tools and Applications in API Development
Arani Chanda (2015)
10.1021/OP000023Y
Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development
Sanjay R. Chemburkar (2000)
10.1002/CEAT.200900478
No Product Design without Process Design (Control)
Torsten Stelzer (2010)
10.1021/OP8001504
Use of a Fiber-Optic Turbidity Probe to Monitor and Control Commercial-Scale Unseeded Batch Crystallizations
R. S. Harner (2009)
10.1021/CG101504C
Combination of a Single Primary Nucleation Event and Secondary Nucleation in Crystallization Processes
Somnath S. Kadam (2011)
10.1021/OP500261Y
Assessment of Recent Process Analytical Technology (PAT) Trends: A Multiauthor Review
L. L. Simon (2015)
10.1016/J.POWTEC.2004.11.040
Organic crystallization processes
E. Paul (2005)
10.1021/CG4002779
Solid-state transformations of sulfathiazole polymorphs: The effects of milling and humidity
Y. Hu (2013)
10.1021/OP400080X
Development and Application of Laboratory Tools To Predict Particle Properties upon Scale-Up in Agitated Filter-Dryers
David J. am Ende (2013)
10.1007/s12247-010-9083-1
A Science and Risk Based Proposal for Understanding Scale and Equipment Dependencies of Small Molecule Drug Substance Manufacturing Processes
David J. am Ende (2010)
10.1021/OP200279M
On the Fracture of Pharmaceutical Needle-Shaped Crystals during Pressure Filtration: Case Studies and Mechanistic Understanding
Claire S. MacLeod (2012)
10.1021/OP9002104
Understanding and Controlling the Formation of an Impurity during the Development of Muraglitazar, a PPAR Dual Agonist
Qingmei Ye (2010)
10.1021/OP049783P
A Review of the Use of Process Analytical Technology for the Understanding and Optimization of Production Batch Crystallization Processes
P. Barrett (2005)
10.1002/AIC.12140
Process control and monitoring of reactive crystallization of L‐glutamic acid
Hannu Alatalo (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar